...
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Prognosis for mammographically occult, early-stage breast cancer patients treated with breast-conservation therapy.
【24h】

Prognosis for mammographically occult, early-stage breast cancer patients treated with breast-conservation therapy.

机译:乳房保守治疗治疗的乳房X线隐匿型早期乳腺癌患者的预后。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To compare mammographically occult (MamOcc) and mammographically positive (MamPos) early-stage breast cancer patients treated with breast-conservation therapy (BCT), to analyze differences between the two cohorts. METHODS AND MATERIALS: Our two cohorts consisted of 214 MamOcc and 2168 MamPos patients treated with BCT. Chart reviews were conducted to assess mammogram reports and method of detection. All clinical-pathologic and outcome parameters were analyzed to detect differences between the two cohorts. RESULTS: Median follow-up was 7 years. There were no differences in final margins, T stage, nodal status, estrogen/progesterone receptor status, or "triple-negative" status. Significant differences included younger age at diagnosis (p < 0.0001), more positive family history (p = 0.0033), less HER-2+ disease (p = 0.0294), and 1 degrees histology (p < 0.0001). At 10 years, the differences in overall survival, cause-specific survival, and distant relapse between the two groups did not differ significantly. The MamOcc cohort had more breast relapses (15% vs. 8%; p = 0.0357), but on multivariate analysis this difference was not significant (hazard ratio 1.0, 95% confidence interval 0.993-1.007, p = 0.9296). Breast relapses were mammographically occult in 32% of the MamOcc and 12% of the MamPos cohorts (p = 0.0136). CONCLUSIONS: Although our study suggests that there are clinical-pathologic variations for the MamOcc cohort vs. MamPos patients that may ultimately affect management, breast relapse after BCT was not significantly different. Breast recurrences were more often mammographically occult in the MamOcc cohort; consideration should be given to closer follow-up and alternative imaging strategies (ultrasound, breast MRI) for routine posttreatment examination. To our knowledge, this represents the largest series addressing the prognostic significance of MamOcc cancers treated with BCT.
机译:目的:比较接受乳房保护术(BCT)治疗的早期乳腺X线摄影(MamOcc)和乳腺X线阳性(MamPos)患者,以分析这两个队列之间的差异。方法和材料:我们的两个队列由214名接受BCT治疗的MamOcc和2168名MamPos患者组成。进行图表审查以评估乳房X线照片报告和检测方法。分析所有临床病理和结果参数以检测两个队列之间的差异。结果:中位随访时间为7年。最终切缘,T分期,淋巴结状态,雌激素/孕激素受体状态或“三阴性”状态没有差异。显着差异包括诊断时年龄更小(p <0.0001),家族史更阳性(p = 0.0033),HER-2 +疾病更少(p = 0.0294)和1度组织学(p <0.0001)。在10年时,两组之间的总生存期,特定原因生存期和远处复发的差异无显着差异。 MamOcc队列的乳腺癌复发率更高(15%对8%; p = 0.0357),但是在多变量分析中,这种差异并不显着(危险比1.0,95%置信区间0.993-1.007,p = 0.9296)。在32%的MamOcc和12%的MamPos人群中,乳房X线照相术均发现乳房复发(p = 0.0136)。结论:尽管我们的研究表明,MamOcc人群与MamPos患者之间存在临床病理差异,可能最终影响治疗,但BCT后的乳腺癌复发无显着差异。在MamOcc研究组中,乳房复发更常见于乳房X线摄影。对于常规的治疗后检查,应考虑采取更密切的随访和替代的成像策略(超声,乳腺MRI)。据我们所知,这是处理BCT治疗的MamOcc癌预后意义的最大系列研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号